Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
Status:
Not yet recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This early phase I trial studies the safety and feasibility of inducing a hypothyroxinemic
state in patients with glioblastoma or gliosarcoma that has come back (recurrent). This trial
aims to see if giving a specific thyroid hormone, such as methimazole and liothyronine, is
safe and could benefit cancer treatment.